A phase III trial of Delpacibart-braxlosiran for Facioscapulohumeral-muscular-dystrophy
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Delpacibart braxlosiran (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Registrational; Therapeutic Use
- 15 Jan 2025 Status changed from not stated to planning.
- 15 Jan 2025 New trial record
- 08 Jan 2025 According to an Avidity Biosciences media release, the company planned to initiate this study in 2Q of 2025.